Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics

Clinical Transplantation

Volumn 14, Issue 3, 2000, Pages 179-188

  Pescovitz, Mark D ^a   Conti, D ^b   Dunn, J ^o   Gonwa, T ^c   Halloran, P ^d   Sollinger, H ^e   Tomlanovich, S ^f   Weinstein, S ^o   Inokuchi, S ^g   Kiberd, B ^h   Kittur, D ⁱ   Merion, R M ^j   Norman, D ^k   Shoker, A ^l   Wilburn, R ^m   Nicholls, A J ⁿ   Arterburn, S ⁿ   Dumont, E ⁿ  

^a INDIANA UNIVERSITY   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h Victoria Transplant Program   (Canada)

ⁱ JOHNS HOPKINS HOSPITAL   (United States)

^j UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l ROYAL UNIVERSITY HOSPITAL   (Canada)

^m VIRGINIA MASON MEDICAL CENTER   (United States)

ⁿ ROCHE BIOSCIENCE   (United States)

^o Indiana University Hospital ^*

more..

Author keywords

Intravenous (i.v.); Kidney transplantation; Mycophenolate mofetil; Pharmacokinetics; Safety

Indexed keywords

CITRIC ACID; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYSORBATE 80;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS CATHETER; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 0034093785     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2000.140301.x     Document Type: Article

References (12)

1. SOLLINGER HW, FOR THE: US RENAL TRANSPLANT MYCOPHENOLATE MOFETIL STUDY GROUP. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
2. THE TRICONTINENTAL MYCOPHENOLATE MOFETIL RENAL TRANSPLANTATION STUDY GROUP. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61 (7): 1029.
3. KOBASHIGAWA J, MILLER L, RENLUND D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998: 66: 507.
4. MATHEW TH, FOR THE TRICONTINENTAL MYCOPHENOLATE MOFETIL RENAL TRANSPLANTATION STUDY GROUP. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998: 65: 1450.
5. LEE WA, GU L, MIKSZTAL AR et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990: 7 (2): 161.
6. EUGUI EM, MIRKOVICH A, ALLISON AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transpl Proc 1991: 23 (2): 15.
7. KIMBALL J, PESCOVITZ MD, BOOK BK et al. Mycophenolate mofetil reduces human IgG anti-ATGAM antibody formation. Transplantation 1995: 60: 1379.
8. SMITH KGC, ISBEL NM, CATTON MG et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transpl 1998: 13: 160.
9. BULLINGHAM R, MONROE S, NICHOLLS A et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in health subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996: 36 (4): 315.
10. BULLINGHAM RES, NICHOLLS AJ, KAMM BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharm 1998: 34 (6): 429.
11. NICHOLLS AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998: 31 (5): 329.
12. SHAW LM, KAPLAN B, BRAYMAN KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem 1998: 44 (2): 381.